Page 2 - Pharma Sector

NITI Aayog proposes 'model pharma chapter' for future FTA negotiations

Think tank flags non-tariff barriers as a bigger hurdle than duties for $35.8 bn drug exports

Aurobindo Pharma gets US FTC nod for $250 million acquisition of Lannett

Aurobindo Pharma on Monday said its arm Aurobindo Pharma USA, Inc has received approval from the US Federal Trade Commission (FTC) for its USD 250 million acquisition of Lannett Company LLC. The transaction, valued at USD 250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end of this month, Aurobindo Pharma said in a regulatory filing. Lannett, a Pennsylvania-based generic pharmaceutical company, specialises in the development and commercialisation of a diversified portfolio of complex, non-opioid controlled substances, the filing said. The acquisition will significantly expand Aurobindo USA's product offering in this segment while adding a US-based manufacturing facility to its network, it added. "This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our US-based manufacturing capabilities, and enhances our position i

Hyderabad firm builds over ₹400 crore pharma biz, without a factory

HRV Pharma owns drug master files and customer relationships while outsourcing production to 53 manufacturing partners, aiming to scale without owning factories

Patent expiry: A $5 bn opportunity for Indian pharma majors, says report

Lupin, Intas Pharmaceuticals, Sun Pharma, MSN Laboratories, Natco Pharma, Zydus Life Sciences and Dr Reddy's Laboratories are some of the companies, the note said, that could potentially benefit.

India's pharma market gets a lift from rising volumes, not just prices

Chronic therapies and GLP-1 adoption help broaden growth drivers as the market expands over 10 per cent in April and May

Biopharma entering innovation power decade, says Bernstein report

Brokerage says India should focus on specialty medicines and incremental innovation rather than copying Big Pharma's new-drug discovery model

Cipla appoints Shivam Puri as CEO of 'One India Business' from July 1

Homegrown pharma major Cipla Ltd on Tuesday announced the appointment of Shivam Puri as the CEO of its 'One India Business' with effect from July 1, 2026. Puri, currently Managing Director and CEO of Cipla Health Ltd, a wholly-owned subsidiary of the company, has over 23 years of leadership experience across both FMCG and healthcare sectors. He brings strong commercial acumen and consumer-centric expertise, Cipla said in a regulatory filing. He took over as MD and CEO of Cipla Health in 2019, and under his leadership, the company rapidly expanded its portfolio and strengthened its presence across key consumer categories, such as smoking cessation, pain care, cough and cold, skin care, hair care and nutrition, among others, Cipla said. Before joining Cipla Health in 2019, Puri held senior leadership roles at Hindustan Unilever, Jubilant FoodWorks and ITC Ltd, the filing said.

Piramal Pharma to stay away from generic GLP-1 race amid global rush

Piramal Pharma is avoiding the crowded GLP-1 peptide market, focusing instead on niche therapies and specialised manufacturing to drive CDMO growth in FY27

India business, margins remain key growth drivers for Torrent Pharma

The stock delivered higher returns than the benchmark Nifty Pharma over the past year

'India pharma resilient despite disruptions; no blanket price hike planned'

India's pharma sector remains resilient despite West Asia disruptions, as the government advances biopharma, R&D and bulk drug manufacturing initiatives

Scheme to build bulk drugs' R&D, capacity in works, says Pharma secy

India plans a new support scheme for bulk drugs focused on R&D and capacity creation, while ruling out a broad medicine price hike despite rising input costs

Uttar Pradesh govt plans to develop pharma ecosystem over 8,000 acres

Uttar Pradesh plans an 8,000-acre healthcare manufacturing ecosystem to attract investments, boost exports and emerge as a major pharma hub

MSME drugmakers face capital stress amid prolonged West Asia disruptions

Cost pressures, inventory strains likely to hit margins by 3-5%

Govt approves Skymap Pharma's ₹121 crore bid for IMPCL stake sale

The Centre approved Skymap Pharmaceuticals' Rs 121 crore bid for the strategic sale of its stake in Indian Medicines Pharmaceutical Corporation Ltd

Anupam Rasayan to acquire up to 43% stake in Bliss GVS Pharma for ₹1,369 cr

Specialty chemicals maker Anupam Rasayan India has signed an agreement to acquire up to 43.3 per cent stake in pharmaceutical formulations company Bliss GVS Pharma Ltd for an estimated Rs 1,369.51 crore and launch an open offer to acquire a further 26 per cent in the firm, according to a statement The Surat-based company will acquire a 43.3 per cent stake at Rs 299 per share for Rs 1,369.51 crore, and launch a mandatory open offer for an additional 26 per cent from public shareholders at the same price, Anupam Rasayan said in a late-night regulatory filing. "We have entered into a definitive agreement to acquire 43.3-48.2 per cent equity stake and are making an open offer to the public shareholders of Bliss GVS Pharma," Anupam Rasayan India Managing Director Anand Desai said. The acquisition will be funded through a Rs 300 crore term loan, with the remaining amount financed via a non-controlling, non-voting equity instrument. "This will strategically strengthen our presence across

High-value clinical research marks gradual shift to India: Parexel

Parexel says India is evolving into a strategic innovation and clinical research hub as global pharmaceutical firms shift high-value functions and decision-making roles

Datanomics: Digital vs traditional in the race for e-pharmacy growth

Traditional pharmacists protest as online pharmacy firms dominate India's drug retail market, outpacing brick-and-mortar players in growth and funding

Torrent Pharma Q4 profit falls 21.9% on high expenses despite revenue boost

Torrent Pharma's Q4 profit dropped 22% as JB Pharma integration costs pushed up expenses, despite strong growth in semaglutide-led revenues

Why pharma stocks are emerging as safe bet amid global market turmoil

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Mankind Pharma Q4 PAT rises 30% on strong domestic biz, chronic push

Mankind Pharma posted a 30.4% rise in Q4FY26 profit, driven by strong demand for chronic therapies and OTC healthcare products